The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome.
Xenotropic murine leukemia virus-related virus (XMRV) is an authentic, newly recognized human retrovirus first identified in prostate cancer tissues from men with a deficiency in the innate immunity gene RNASEL. At present, studies have detected XMRV at widely different rates in prostate cancer cases (0-27%) and in patients with chronic fatigue syndrome (CFS; 0-67%). Indirect or direct modes of carcinogenesis by XMRV have been suggested depending on whether the virus was found in stroma or malignant epithelium. Viral replication in the prostate might be affected by androgens, which stimulate XMRV through a transcriptional enhancer site in viral DNA. By contrast, host restriction factors, such as APOBEC3 and tetherin, inhibit virus replication. Immune dysfunction mediated by XMRV has been suggested as a possible factor in CFS. Recent studies show that some existing antiretroviral drugs suppress XMRV infections and diagnostic assays are under development. Although other retroviruses of the same genus as XMRV (gammaretroviruses) cause cancer and neurological disease in animals, whether XMRV is a cause of either prostate cancer or CFS remains unknown. Emerging science surrounding XMRV is contributing to our knowledge of retroviral infections while focusing intense interest on two major human diseases.
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. silverr@ccf.org
Robert H
RH
Silverman
Carvell
C
Nguyen
Christopher J
CJ
Weight
Eric A
EA
Klein
D044966:Anti-Retroviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D015673:Fatigue Syndrome, Chronic / Q000276:immunology / Q000628:therapy / Q000821:virology*; D005260:Female; D017988:Gammaretrovirus / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D006801:Humans; D009052:Leukemia Virus, Murine / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy / Q000821:virology*; D012190:Retroviridae / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D012192:Retroviridae Infections / Q000276:immunology / Q000628:therapy / Q000821:virology*; D014412:Tumor Virus Infections / Q000276:immunology / Q000628:therapy / Q000821:virology*
D044966:Anti-Retroviral Agents